Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 16/20 | 0.49 |
| ▸ | AKT2 | P31751 | 7/20 | 0.46 |
| ▸ | GSK3B | P49841 | 3/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4909756 | 0.83 | AKT1 (0.53) | AKT1AKT2GSK3B | |
| SCHEMBL473370 | 0.83 | AKT1 (0.43) | AKT1AKT2GSK3BCYP2C9CYP2D6 | |
| SCHEMBL13885616 | 0.82 | AKT2 (0.68) | AKT1AKT2CYP2C9ROCK2KCNH2 | |
| SCHEMBL473311 | 0.79 | MEN1 (0.50) | AKT1RPS6KB1 | |
| SCHEMBL2797432 | 0.76 | AKT1 (0.70) | AKT1AKT2AKT3 | |
| SCHEMBL2797435 | 0.76 | AKT1 (0.70) | AKT1AKT2AKT3 | |
| SCHEMBL390598 | 0.76 | AKT1 (0.81) | AKT1AKT2RPS6KB1ROCK2KCNH2 | |
| SCHEMBL1790785 | 0.76 | RPS6KB1 (0.47) | AKT1RPS6KB1 | |
| SCHEMBL390670 | 0.75 | AKT1 (0.82) | AKT1AKT2RPS6KB1ROCK2KCNH2 | |
| SCHEMBL3032138 | 0.75 | AKT1 (0.43) | AKT1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188482-A1 | [1H-Pyrazolo[3, 4-D]Pyrimidin-4-Yl]-Piperidine or -Piperazine Compounds as Serine-Theoronine Kinase Modulators (P70s6k, Atk1 and Atk2) for the Treatment of Immunological, Inflammatory and Proliferative Diseases | EXELIXIS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| EP-1848719-A1 | [1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-YL]-PIPERIDINE OR -PIPERAZINE COMPOUNDS AS SERINE-THREONINE KINASE MODULATORS (P70S6K, ATK1 AND ATK2) FOR THE TREATMENT OF IMMUNOLOGICAL, INFLAMMATORY AND PROLIFERATIVE DISEASES | Exelixis, Inc. (US) | 2007-10-31 | — | — | EP | disclosed |
| WO-2006071819-A1 | [1H-PYRAZOLO[3, 4-D]PYRIMIDIN-4-YL]-PIPERIDINE OR -PIPERAZINE COMPOUNDS AS SERINE-THEORONINE KINASE MODULATORS (P70S6K, ATK1 AND ATK2) FOR THE TREATMENT OF IMMUNOLOGICAL, INFLAMMATORY AND PROLIFERATIVE DISEASES | EXELIXIS, INC. (US) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188482-A1 | [1H-Pyrazolo[3, 4-D]Pyrimidin-4-Yl]-Piperidine or -Piperazine Compounds as Serine-Theoronine Kinase Modulators (P70s6k, Atk1 and Atk2) for the Treatment of Immunological, Inflammatory and Proliferative Diseases | PDPK1, MTOR, RPS6KA2 | AKT1 14/4885AKT2 6/4885GSK3B 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.